X

Drug Profile

Omalizumab biosimilar - CinnaGen

Latest Information Update: 20 Apr 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator CinnaGen
Class Antiallergics; Antiasthmatics; Monoclonal antibodies; Skin disorder therapies
Mechanism of Action IgE receptor antagonists; Immunosuppressants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Phase III Allergic asthma

Most Recent Events

15 Jan 2023 Cinnagen completes a phase-III clinical trials in Allergic asthma in Iran (IV) (IRCT20150303021315N20) (NCT05813470)
18 Jan 2021 Phase-III clinical trials in Allergic asthma in Iran (IV) (IRCT20150303021315N20) (NCT05813470)
06 Aug 2020 CinnaGen plans a phase III trial for Allergic asthma in Iran (IV) (IRCT20150303021315N20)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com